An analysis in JDDG: Journal der Deutschen Dermatologischen Gesellschaft found that people with eczema (also known as atopic dermatitis) face an elevated risk of developing shingles (or herpes zoster).
Eczema is a chronic inflammatory skin condition, while shingles presents as a painful rash when the virus that causes chicken pox reactivates in the nervous system, particularly later in life or in immunosuppressed individuals.
When researchers analyzed 1997–2023 primary care information pertaining to 113,426,267 people listed in a UK database, they found that individuals with eczema had a 28% higher risk of developing shingles after adjusting for other influencing factors such as age, sex, comorbidities, cigarette smoking, and alcohol use. Use of immunosuppressant medications had a minimal effect on shingles risk. Also, shingles risk increased with the severity of eczema.
Mechanistically, an altered skin immune response in people with eczema may put them at risk of developing shingles.
“These findings may inform vaccination guidelines,” the authors wrote.
URL: https://onlinelibrary.wiley.com/doi/10.1111/ddg.70329
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
The JDDG: Journal der Deutschen Dermatologischen Gesellschaft is a dermatology journal publishing scientific papers from a wide range of disciplines, such as dermatovenereology, allergology, phlebology, dermatosurgery, dermatooncology, and dermatohistopathology. Also in JDDG: information on medical training, continuing education, a calendar of events, book reviews, and society announcements. Papers can be submitted in German or English language. In the print version, all articles are published in German. In the online version, all key articles are published in English.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.